BD, B. Braun Melsungen AG and Johnson & Johnson Services, Inc. (Ethicon LLC) – Notable Market Participants in Hemostats Industry
Hemostats refers to surgical supplies that helps to control blood loss and consists of hemostatic agents present in the form of pads, sponges, patches, powders, liquids or others. Factors such as increasing number of surgical procedures, increasing incidence of sports injuries and technological advancements in hemostats are expected to account for the growth of the market.
The most notable market participants are Johnson & Johnson Services, Inc. (Ethicon LLC), BD, Baxter, B. Braun Melsungen Ag, Pfizer, Inc., GELITA MEDICAL, Integra Lifesciences Holdings Corporation, Z-Medica, LLC, Biom’up, and Teleflex Incorporated occupying a considerable share of the market owing to their offerings to the market.
Market leaders are involved in inorganic activities such as partnerships and acquisitions in order to improve their performance and consolidate market position. For instance, in March 2018, Baxter acquired commercial rights of two products RECOTHROM and PREVELEAK from Mallinckrodt plc. These two products are expected to offer additional customer base in surgical care portfolio of the company. The product, RECOTHROM, in the only recombinant thrombin hemostat which can be used in any type of surgical procedure.
Prominent players in hemostats market are also focusing on organic strategies such as product launch, product approval, geographic and manufacturing expansion, and others. These strategies are helping major players to strengthen their market positions along with widening their geographic footprints. Additionally, various companies are also undergoing other strategic alliances such as acquisitions and others to garner their significance and remain competitive in the market. Few of the important key developments from the industry are mentioned below:
|
Year |
News |
Region |
|
2019 |
Baxter International, Inc. received FDA approval for its newly developed hemostat, Floseal. |
North America |
|
2019 |
Biom’up SA specializing in surgical hemostasis, announced its flagship product, HEMOBLAST Bellows, to be approved for open as well as laparoscopic surgery by the Australian TGA regulatory authority for commercialization in the sizable and growing Australian market. |
Asia Pacific |
|
2018 |
Ethicon, part of the Johnson & Johnson Medical Devices Companies, announced the U.S. launch of SURGICEL POWDER ABSORBABLE HEMOSTAT, a powdered adjunctive hemostat, designed to help surgeons control disruptive bleeding more efficiently. |
North America |
